Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | TLR4 | O00206 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22804147 | 0.81 | AKR1C4 (0.53) | AKR1C4AKR1C3AKR1C2TLR4TDP1 | |
| SCHEMBL14035897 | 0.81 | AKR1C4 (0.53) | AKR1C4AKR1C3AKR1C2TLR4TDP1 | |
| SCHEMBL19736432 | 0.76 | BRD4 (0.39) | AKR1C4AKR1C3AKR1C2TLR4 | |
| SCHEMBL14468370 | 0.76 | BRD4 (0.39) | AKR1C4AKR1C3AKR1C2TLR4 | |
| SCHEMBL13523241 | 0.76 | AKR1C4 (0.36) | AKR1C4AKR1C3AKR1C2TLR4 | |
| SCHEMBL12189850 | 0.76 | AKR1C4 (0.37) | AKR1C4AKR1C3AKR1C2TLR4 | |
| SCHEMBL10053671 | 0.75 | AKR1C4 (0.33) | AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL14305274 | 0.74 | — | — | |
| SCHEMBL11841597 | 0.74 | AKR1C4 (0.43) | AKR1C4AKR1C3AKR1C2TLR4 | |
| SCHEMBL20251126 | 0.73 | AKR1C4 (0.37) | AKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD (IL) | 2012-04-05 | — | — | US | disclosed |
| US-20090197927-A1 | JASMONATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | SEPAL PHARMA LTD. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197927-A1 | JASMONATE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALOX5, GGPS1, PPIP5K2 | AKR1C4 1945/4885AKR1C3 1678/4885AKR1C2 1420/4885 |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | MYC, KRT18, DGKK | AKR1C4 390/4885AKR1C3 401/4885AKR1C2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.